Zai Lab announces updates to China’s National Reimbursement Drug List

Zai Lab (ZLAB) announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List, NRDL, released by China’s National Healthcare Security Administration, NHSA: VYVGART is renewed for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive; NUZYRA is renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; and ZEJULA is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.